The study focuses on Non-Small Cell Lung Cancer, a common type of lung cancer that has grown beyond the original site or spread to other parts of the body. This condition can cause symptoms such as coughing, shortness of breath, and chest pain, and it is usually treated with a combination of medicines that try to shrink or stop the growth of the tumor.
Participants will receive an intravenous infusion of a new medicine called Imzokitug together with Pumitamig and a chemotherapy regimen known as Platinum-Doublet Chemotherapy. The chemotherapy uses two platinum‑based drugs that work by damaging the DNA of cancer cells, making it harder for them to grow. In the comparison group, patients will receive only Pumitamig and the same chemotherapy without the experimental drug. All medicines are given through a vein, usually every few weeks, and doctors will watch for side effects such as nausea, fatigue, or changes in blood counts.
The purpose of the trial is to see whether adding the experimental drug improves the proportion of patients whose tumors shrink or disappear, a measure called the objective response rate. Throughout the study, doctors will measure tumor size with imaging scans and evaluate the changes using criteria called RECIST, which provide a standard way to decide if a tumor has gotten smaller, stayed the same, or grown. Participants will be followed for several months after treatment to track how long any tumor shrinkage lasts, how long they stay without disease worsening, and overall survival, while safety is continually monitored.
Germany 
Italy 
